Liquid melatonin via gastrostomy as an alternative hypnotic in a child with pervasive developmental disorder.

Yakov Sherk,Beth A. Smith,B. Miller

DOI: https://doi.org/10.1089/cap.2010.0088

2011-06-10

Journal of Child and Adolescent Psychopharmacology

Abstract:

What problem does this paper attempt to address?

Enhanced N-Glycan Profiling of Therapeutic Monoclonal Antibodies through the Application of Upper-Hinge Middle-Up Level LC-HRMS Analysis

Natalia Mesonzhnik,Anton Belushenko,Polina Novikova,Alexey Kukharenko,Mikhail Afonin

DOI: https://doi.org/10.3390/antib13030066

2024-08-06

Abstract:Therapeutic monoclonal antibodies (mAbs) are crucial in modern medicine due to their effectiveness in treating various diseases. However, the structural complexity of mAbs, particularly their glycosylation patterns, presents challenges for quality control and biosimilarity assessment. This study explores the use of upper-hinge middle-up (UHMU)-level ultra-high-performance liquid chromatography-high-resolution mass spectrometry (LC-HRMS) analysis to improve N-glycan profiling of mAbs. Two specific enzymes, known as IgG degradation enzymes (IGDEs), were used to selectively cleave therapeutic mAbs above the hinge region to separate antibody subunits for further Fc glycan analysis by means of the UHMU/LC-HRMS workflow. The complexity of the mass spectra of IGDEs-digested mAbs was significantly reduced compared to the intact MS level, enabling reliable assignment and relative quantitation of paired Fc glycoforms. The results of the UHMU/LC-HRMS analysis of nine approved therapeutics highlight the significance of this approach for in-depth glycoform profiling.
Amish albinism: a distinctive autosomal recessive phenotype.

Walter E. Nance,'. C. E. Jackson,Carl J. Witkop

1970-09-01

Abstract:Evidence for extensive genetic heterogeneity among various forms of albinism has long been available in lower animals (Searle 1968 ). More recently, biochemical and genetic studies have demonstrated the existence of at least two different forms of generalized oculocutaneous albinism in man (Witkop et al. 1970). We wish to describe an additional autosomal recessive form of albinism observed in 10 members of four related consanguineous Amish sibships. The clinical and laboratory findings in affected individuals were quite similar and appear to constitute a distinctive. "new" phenotype.
Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development

Harleen Kaur

DOI: https://doi.org/10.1080/07388551.2020.1869684

IF: 9.062

2021-01-11

Critical Reviews in Biotechnology

Abstract:<span>Glycosylation is one of the structurally diverse and complex forms of post translational modifications observed in proteins which influence the effector functions of IgG-Fc. Although the glycosylation constitutes 2–3% of the total mass of the IgG antibody, a thorough assessment of glycoform distribution present on the antibody is a critical quality attribute (cQA) for the majority of novel and biosimilar monoclonal antibody (mAb) development. This review paper will highlight the impact of different glycoforms such as galactose, fucose, high mannose, NANA (N-acetylneuraminic acid), and NGNA (N-glycoylneuraminic acid) on the safety/immunogeneicity, efficacy/biological activity and clearance (pharmacodynamics/pharmacokinetic property (PD/PK)) of biological molecules. In addition, this paper will summarize routinely employed reliable analytical techniques such as hydrophilic interaction chromatography (HILIC), high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) and mass spectrometry (MS) for characterizing and monitoring glycosylation in monoclonal antibodies (mAbs). The advantages and disadvantages of each of the methods are addressed. The scope of this review paper is limited to only N-linked and O-linked glycosylation.</span>

biotechnology & applied microbiology
Noninvasive High-Throughput Single-Cell Analysis of the Intracellular pH of Saccharomyces cerevisiae by Ratiometric Flow Cytometry

M. Valkonen,D. Mojzita,M. Penttilä,M. Benčina

DOI: https://doi.org/10.1128/AEM.02515-13

2013-09-13

Applied and Environmental Microbiology

Abstract:ABSTRACT The ability of cells to maintain pH homeostasis in response to environmental changes has elicited interest in basic and applied research and has prompted the development of methods for intracellular pH measurements. Many traditional methods provide information at population level and thus the average values of the studied cell physiological phenomena, excluding the fact that cell cultures are very heterogeneous. Single-cell analysis, on the other hand, offers more detailed insight into population variability, thereby facilitating a considerably deeper understanding of cell physiology. Although microscopy methods can address this issue, they suffer from limitations in terms of the small number of individual cells that can be studied and complicated image processing. We developed a noninvasive high-throughput method that employs flow cytometry to analyze large populations of cells that express pHluorin, a genetically encoded ratiometric fluorescent probe that is sensitive to pH. The method described here enables measurement of the intracellular pH of single cells with high sensitivity and speed, which is a clear improvement compared to previously published methods that either require pretreatment of the cells, measure cell populations, or require complex data analysis. The ratios of fluorescence intensities, which correlate to the intracellular pH, are independent of the expression levels of the pH probe, making the use of transiently or extrachromosomally expressed probes possible. We conducted an experiment on the kinetics of the pH homeostasis of Saccharomyces cerevisiae cultures grown to a stationary phase after ethanol or glucose addition and after exposure to weak acid stress and glucose pulse. Minor populations with pH homeostasis behaving differently upon treatments were identified.
Histochemistry of nerve fibres double labelled with anti-TRPV2 antibodies and sensory nerve marker AM1-43 in the dental pulp of rat molars.

S. Nishikawa

DOI: https://doi.org/10.1016/j.archoralbio.2008.03.001

IF: 2.64

2008-09-01

Archives of Oral Biology

Abstract:
The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies

Elsa Wagner-Rousset,Audrey Bednarczyk,Marie-Claire Bussat,Olivier Colas,Nathalie Corvaïa,Christine Schaeffer,Alain Van Dorsselaer,Alain Beck

DOI: https://doi.org/10.1016/j.jchromb.2008.03.032

2008-09-01

Abstract:Glycosylation which plays a crucial role in the pharmacological properties of therapeutic monoclonal antibodies (MAbs) is influenced by several factors like production systems, selected clonal population and manufacturing processes. Efficient analytical methods are therefore required in order to characterize glycosylation at different stages of MAbs discovery and production. Three mass spectrometry (MS)-based strategies were compared to analyze N-glycosylation of MAbs either expressed in murine myeloma (NS0) or Chinese Hamster Ovary (CHO) cell lines, the two current main production systems used for therapeutic MAbs. First a top-down approach was used on intact and reduced MAbs by liquid chromatography coupled to an electrospray ionization-time of flight mass spectrometer (LC-ESI-TOF), which provided fast and accurate profiles of MAbs glycosylation patterns for routine controls. Secondly, after digestion of the antibody with the peptide N-glycosidase F (PNGase F) enzyme, released N-linked glycans were directly analyzed by electrospray ionization-tandem mass spectrometry (ESI-MS/MS) without any prior derivatization, which gave precise details on the structure of the most abundant glycoforms. Finally, a bottom-up approach on tryptic glycopeptides using a nanoLC-Chip-MS/MS ion trap (IT) system equipped with a graphitized carbon column was investigated. Data were compared to those obtained with a more classical C18 reversed phase column showing that this last method is well suited to detect low abundant glycoforms and to provide in one shot information regarding both the oligosaccharide structure and the amino acid sequence of its peptide moiety.
Development and validation of a platform reduced intact mass method for process monitoring of monoclonal antibody glycosylation during routine manufacturing

Michael Schilling,Pamela Feng,Zoran Sosic,Stacey L. Traviglia

DOI: https://doi.org/10.1080/21655979.2020.1842651

2020-01-01

Bioengineered

Abstract:N-linked glycosylation is a primary source of heterogeneity associated with recombinant monoclonal antibodies and plays a key role in a myriad of drug properties associated with biological function. The glycosylation profile of recombinant monoclonal antibodies is influenced by an array of cell culture inputs which must be carefully controlled in order to engineer the desired glycan distribution. A platform reduced intact mass method applied to monoclonal antibodies has been validated as a quantitative method to monitor the relative mannose-5 level as a surrogate for overall high mannose content in cell culture as a control strategy to ensure product quality and process consistency. The method was shown to be linear, accurate, specific, and precise for an IgG1 and IgG4 mAb allowing relative quantitation of mannose-5 in the range 0.8-11.0% and 1.0-6.2%, respectively. The method can be applied at several stages of the production process from cell culture harvest to drug substance/drug product and is amenable to routine GMP batch testing in a quality control laboratory. Testing upstream during cell culture rather than for product release allows for an earlier assessment of product quality as the glycosylation profile remains unchanged during downstream purification.

biotechnology & applied microbiology
Plan and process for hematology laboratory standard in Thailand.

A. Bunyaratvej

Southeast asian journal of tropical medicine and public health

Abstract:In Thailand, there are around 2,000 clinical laboratories in private and government hospitals, By the end of year 2004, all of these laboratories are required to use the same or comparable standard nationwide. Many laboratories are in the process of starting ISO/IEC Guide 25 for the fulfillment of laboratory accreditation. To run the standard system of hematology laboratories in Thailand, we have considered three main aspects: standard in process, method selection and academic interpretation. Because of the wide spectrum of blood diseases in Thailand: thalassemia, iron deficiency anemia and G6PD deficiency hemolytic disease, the analysis and interpretation of laboratory results using different technology are of great importance. National plan has thus set up in two direction, one for standard process and another for academic approach.
Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform

Ngan T B Nguyen,Hau Wan Leung,Kuin Tian Pang,Shi Jie Tay,Ian Walsh,Andre B H Choo,Yuansheng Yang

DOI: https://doi.org/10.1038/s41598-023-42925-1

2023-09-20

Abstract:Monoclonal antibodies (mAbs) eliminate cancer cells via various effector mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are influenced by the N-glycan structures on the Fc region of mAbs. Manipulating these glycan structures on mAbs allows for optimization of therapeutic benefits associated with effector functions. Traditional approaches such as gene deletion or overexpression often lead to only all-or-nothing changes in gene expression and fail to modulate the expression of multiple genes at defined ratios and levels. In this work, we have developed a CHO cell engineering platform enabling modulation of multiple gene expression to tailor the N-glycan profiles of mAbs for enhanced effector functions. Our platform involves a CHO targeted integration platform with two independent landing pads, allowing expression of multiple genes at two pre-determined genomic sites. By combining with internal ribosome entry site (IRES)-based polycistronic vectors, we simultaneously modulated the expression of α-mannosidase II (MANII) and chimeric β-1,4-N-acetylglucosaminyl-transferase III (cGNTIII) genes in CHO cells. This strategy enabled the production of mAbs carrying N-glycans with various levels of bisecting and non-fucosylated structures. Importantly, these engineered mAbs exhibited different degrees of effector cell activation and CDC, facilitating the identification of mAbs with optimal effector functions. This platform was demonstrated as a powerful tool for producing antibody therapeutics with tailored effector functions via precise engineering of N-glycan profiles. It holds promise for advancing the field of metabolic engineering in mammalian cells.
Spectrographic representation of globular protein breathing motions.

C. Pickover

DOI: https://doi.org/10.1126/SCIENCE.6691144

IF: 56.9

1984-01-13

Science

Abstract:Two useful ways of describing the frequency composition of the breathing motions of globular proteins are the spectrogram and three-dimensional power spectrum, representations similar to those frequently used in speech analysis. In this report "low-frequency" vibrations of globular proteins, corresponding to the collective oscillations of atoms from many different residues, are considered. Radii of gyration fluctuations provide a sensitive way to characterize such concerted motions.
Sculpting therapeutic monoclonal antibody N-glycans using endoglycosidases

Beatriz Trastoy,Mikel García-Alija,Chao Li,Lai-Xi Wang,Jonathan J. Du,Erik H. Klontz,Eric J. Sundberg,Marcelo E. Guerin

DOI: https://doi.org/10.1016/j.sbi.2021.11.016

IF: 7.786

2022-02-01

Current Opinion in Structural Biology

Abstract:Immunoglobulin G (IgG) monoclonal antibodies are a prominent and expanding class of therapeutics used for the treatment of diverse human disorders. The chemical composition of the N-glycan on the fragment crystallizable (Fc) region determines the effector functions through interaction with the Fc gamma receptors and complement proteins. The chemoenzymatic synthesis using endo-β-N-acetylglucosaminidases (ENGases) emerged as a strategy to obtain antibodies with customized glycoforms that modulate their therapeutic activity. We discuss the molecular mechanism by which ENGases recognize different N-glycans and protein substrates, especially those that are specific for IgG antibodies, in order to rationalize the glycoengineering of immunotherapeutic antibodies, which increase the impact on the treatment of myriad diseases.

cell biology,biochemistry & molecular biology
Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering

Xiaojie Yu,Michael J. E. Marshall,Mark S. Cragg,Max Crispin

DOI: https://doi.org/10.1007/s40259-017-0223-8

IF: 7.744

2017-01-01

BioDrugs

Abstract:Antibody-based therapeutics has emerged as a major tool in cancer treatment. Guided by the superb specificity of the antibody variable domain, it allows the precise targeting of tumour markers. Recently, eliciting cellular effector functions, mediated by the Fc domain, has gained traction as a means by which to generate more potent antibody therapeutics. Extensive mutagenesis studies of the Fc protein backbone has enabled the generation of Fc variants that more optimally engage the Fcγ receptors known to mediate cellular effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and cellular phagocytosis. In addition to the protein backbone, the homodimeric Fc domain contains two opposing N-linked glycans, which represent a further point of potential immunomodulation, independent of the Fc protein backbone. For example, a lack of core fucose usually attached to the IgG Fc glycan leads to enhanced ADCC activity, whereas a high level of terminal sialylation is associated with reduced inflammation. Significant growth in knowledge of Fc glycosylation over the last decade, combined with advancement in genetic engineering, has empowered glyco-engineering to fine-tune antibody therapeutics. This has culminated in the approval of two glyco-engineered antibodies for cancer therapy: the anti-CCR4 mogamulizumab approved in 2012 and the anti-CD20 obinutuzumab in 2013. We discuss here the technological platforms for antibody glyco-engineering and review the current clinical landscape of glyco-engineered antibodies.
Identifying a robust design space for glycosylation during monoclonal antibody production

Melissa M. St. Amand,James Hayes,Devesh Radhakrishnan,Janice Fernandez,Bill Meyer,Anne S. Robinson,Babatunde A. Ogunnaike

DOI: https://doi.org/10.1002/btpr.2316

IF: 2.9

2016-07-01

Biotechnology Progress

Abstract:Glycan distribution has been identified as a "critical quality attribute" for many biopharmaceutical products, including monoclonal antibodies. Consequently, determining quantitatively how process variables affect glycan distribution is important during process development to control antibody glycosylation. In this work, we assess the effect of six bioreactor process variables on the glycan distribution of an IgG1 produced in CHO cells. Our analysis established that glucose and glutamine media concentration, temperature, pH, agitation rate, and dissolved oxygen (DO) had small but significant effects on the relative percentage of various glycans. In addition, we assessed glycosylation enzyme transcript levels and intracellular sugar nucleotide concentrations within the CHO cells to provide a biological explanation for the observed effects on glycan distributions. From these results we identified a robust operating region, or design space, in which the IgG1 could be produced with a consistent glycan distribution. Since our results indicate that perturbations to bioreactor process variables will cause only small (even if significant) changes to the relative percentage of various glycans (<±1.5%)-changes that are too small to affect the bioactivity and efficacy of this IgG1 significantly-it follows that the glycan distribution obtained will be consistent even with relatively large variations in bioreactor process variables. However, for therapeutic proteins where bioactivity and efficacy are affected by small changes to the relative percentage of glycans, the same analysis would identify the manipulated variables capable of changing glycan distribution, and hence can be used to implement a glycosylation control strategy. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:1149-1162, 2016.

biotechnology & applied microbiology,food science & technology
Host cell proteins in monoclonal antibody processing: Control, detection, and removal

Takao Ito,Herb Lutz,Lihan Tan,Bin Wang,Janice Tan,Masum Patel,Lance Chen,Yuki Tsunakawa,Byunghyun Park,Subhasis Banerjee

DOI: https://doi.org/10.1002/btpr.3448

IF: 2.9

2024-03-15

Biotechnology Progress

Abstract:Host cell proteins (HCPs) are process‐related impurities in a therapeutic protein expressed using cell culture technology. This review presents biopharmaceutical industry trends in terms of both HCPs in the bioprocessing of monoclonal antibodies (mAbs) and the capabilities for HCP clearance by downstream unit operations. A comprehensive assessment of currently implemented and emerging technologies in the manufacturing processes with extensive references was performed. Meta‐analyses of published downstream data were conducted to identify trends. Improved analytical methods and understanding of "high‐risk" HCPs lead to more robust manufacturing processes and higher‐quality therapeutics. The trend of higher cell density cultures leads to both higher mAb expression and higher HCP levels. However, HCP levels can be significantly reduced with improvements in operations, resulting in similar concentrations of approx. 10 ppm HCPs. There are no differences in the performance of HCP clearance between recent enhanced downstream operations and traditional batch processing. This review includes best practices for developing improved processes.

biotechnology & applied microbiology,food science & technology
Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.

Amy W Chung,Max Crispin,Laura Pritchard,Hannah Robinson,Miroslaw K Gorny,Xiaojie Yu,Chris Bailey-Kellogg,Margaret E Ackerman,Chris Scanlan,Susan Zolla-Pazner,Galit Alter

DOI: https://doi.org/10.1097/QAD.0000000000000444

IF: 4.632

2014-01-01

AIDS

Abstract:Objective: To determine monoclonal antibody (mAb) features that predict fragment crystalizable (Fc)-mediated effector functions against HIV. Design: Monoclonal antibodies, derived from Chinese hamster ovary cells or Epstein-Barr virus-immortalized mouse heteromyelomas, with specificity to key regions of the HIV envelope including gp120-V2, gp120-V3 loop, gp120-CD4(+) binding site, and gp41-specific antibodies, were functionally profiled to determine the relative contribution of the variable and constant domain features of the antibodies in driving robust Fc-effector functions. Methods: Each mAb was assayed for antibody-binding affinity to gp140(SF162), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and for the ability to bind to Fc gamma RIIa, Fc gamma RIIb and Fc gamma RIIIa receptors. Antibody glycan profiles were determined by HPLC. Results: Neither the specificity nor the affinity of the mAbs determined the potency of Fc-effector function. Fc gamma RIIIa binding strongly predicted ADCC and decreased galactose content inversely correlated with ADCP, whereas N-glycolylneuraminic acidcontaining structures exhibited enhanced ADCP. Additionally, the bi-antenary glycan arm onto which galactose was added predicted enhanced binding to Fc gamma RIIIa and ADCC activity, independent of the specificity of the mAb. Conclusions: Our studies point to the specific Fc-glycan structures that can selectively promote Fc-effector functions independently of the antibody specificity. Furthermore, we demonstrated antibody glycan structures associated with enhanced ADCP activity, an emerging Fc-effector function that may aid in the control and clearance of HIV infection. (c) 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
Production , Manufacturing and Logistics Multi-source facility location – allocation and inventory problem

Zhishuang Yao,L. Lee,W. Jaruphongsa,Vicky Tan,C. Hui

Abstract:Article history: Received 13 May 2009 Accepted 7 June 2010 Available online 16 June 2010
The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies

Patricia Gogesch,Simone Dudek,Ger van Zandbergen,Zoe Waibler,Martina Anzaghe

DOI: https://doi.org/10.3390/ijms22168947

IF: 5.6

2021-08-19

International Journal of Molecular Sciences

Abstract:Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are approved for the European market for a broad range of clinical indications. In order to ensure clinical efficacy and safety aspects, (pre-)clinical experimental approaches evaluate the respective modes of action (MoA). In addition to antigen-specificity including binding affinity and -avidity, MoA comprise Fc-mediated effector functions such as antibody dependent cellular cytotoxicity (ADCC) and the closely related antibody dependent cellular phagocytosis (ADCP). For this reason, a variety of cell-based assays have been established investigating effector functions of therapeutic mAbs with different effector/target-cell combinations and several readouts including Fcγ receptor (FcγR)-mediated lysis, fluorescence, or luminescence. Optimized FcγR-mediated effector functions regarding clinical safety and efficacy are addressed with modification strategies such as point mutations, altered glycosylation patterns, combination of different Fc subclasses (cross isotypes), and Fc-truncation of the mAb. These strategies opened the field for a next generation of therapeutic mAbs. In conclusion, it is of major importance to consider FcγR-mediated effector functions for the efficacy of therapeutic mAbs.

biochemistry & molecular biology,chemistry, multidisciplinary
Assessment of monoclonal antibody glycosylation: a comparative study using HRMS, NMR, and HILIC-FLD

DOI: https://doi.org/10.1007/s00216-024-05261-5

2024-04-07

Analytical and Bioanalytical Chemistry

Abstract:Monoclonal antibodies (mAbs) represent the largest class of therapeutic protein drug products. mAb glycosylation produces a heterogeneous, analytically challenging distribution of glycoforms that typically should be adequately characterized because glycosylation-based product quality attributes (PQAs) can impact product quality, immunogenicity, and efficacy. In this study, two products were compared using a panel of analytical methods. Two high-resolution mass spectrometry (HRMS) workflows were used to analyze N-glycans, while nuclear magnetic resonance (NMR) was used to generate monosaccharide fingerprints. These state-of-the-art techniques were compared to conventional analysis using hydrophilic interaction chromatography (HILIC) coupled with fluorescence detection (FLD). The advantages and disadvantages of each method are discussed along with a comparison of the identified glycan distributions. The results demonstrated agreement across all methods for major glycoforms, demonstrating how confidence in glycan characterization is increased by combining orthogonal analytical methodologies. The full panel of methods used represents a diverse toolbox that can be selected from based on the needs for a specific product or analysis.

chemistry, analytical,biochemical research methods
A low‐temperature SPR‐based assay for monoclonal antibody galactosylation and fucosylation assessment using FcγRIIA/B

Jimmy Gaudreault,Catherine Forest‐Nault,Michel Gilbert,Yves Durocher,Olivier Henry,Gregory De Crescenzo

DOI: https://doi.org/10.1002/bit.28673

IF: 3.8

2024-02-16

Biotechnology and Bioengineering

Abstract:Gaudreault and coworkers present a novel analysis method for the inference of antibody glycosylation from surface plasmon resonance (SPR) data of the interaction with Fc receptors. Rather than fitting an interaction model, the area under the dissociation phase of the SPR curve is used as a metric to discriminate galactosylated glycoforms (with FcRIIA) and fucosylated glycoforms (with FcRIIB). Furthermore, they show that reducing the experimental temperature amplifies the differences in the dissociation behavior of different glycoforms for a given Fc receptor. Monoclonal antibodies (MAbs) are powerful therapeutic tools in modern medicine and represent a rapidly expanding multibillion USD market. While bioprocesses are generally well understood and optimized for MAbs, online quality control remains challenging. Notably, N‐glycosylation is a critical quality attribute of MAbs as it affects binding to Fcγ receptors (FcγRs), impacting the efficacy and safety of MAbs. Traditional N‐glycosylation characterization methods are ill‐suited for online monitoring of a bioreactor; in contrast, surface plasmon resonance (SPR) represents a promising avenue, as SPR biosensors can record MAb–FcγR interactions in real‐time and without labeling. In this study, we produced five lots of differentially glycosylated Trastuzumab (TZM) and finely characterized their glycosylation profile by HILIC‐UPLC chromatography. We then compared the interaction kinetics of these MAb lots with four FcγRs including FcγRIIA and FcγRIIB at 5°C and 25°C. When interacting with FcγRIIA/B at low temperature, the differentially glycosylated MAb lots exhibited distinct kinetic behaviors, contrary to room‐temperature experiments. Galactosylated TZM (1) and core fucosylated TZM (2) could be discriminated and even quantified using an analytical technique based on the area under the curve of the signal recorded during the dissociation phase of a SPR sensorgram describing the interaction with FcγRIIA (1) or FcγRII2B (2). Because of the rapidity of the proposed method (<5 min per measurement) and the small sample concentration it requires (as low as 30 nM, exact concentration not required), it could be a valuable process analytical technology for MAb glycosylation monitoring.

biotechnology & applied microbiology
The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions

Qiong Wang,Tiexin Wang,Roushu Zhang,Shuang Yang,Kevin S. McFarland,Cheng‐Yu Chung,Hongpeng Jia,Lai‐Xi Wang,John F. Cipollo,Michael J. Betenbaugh

DOI: https://doi.org/10.1002/bit.27953

IF: 3.8

2021-10-20

Biotechnology and Bioengineering

Abstract:The N-glycan pattern of an IgG antibody, attached at a conserved site within the Fc region, is a critical antibody quality attribute whose structural variability can also impact antibody function. For tailoring the Fc glycoprofile, glycoengineering in cell lines as well as Fc amino acid mutations have been applied. Multiple glycoengineered CHO cell lines were generated, including defucosylated (FUT8KO), α-2,6-sialylated (ST6KI) and defucosylated α-2,6-sialylated (FUT8KOST6KI), expressing either a wild-type anti-CD20 IgG (WT) or phenylalanine to alanine (F241A) mutant. MALDI-TOF MS characterization of antibody N-glycans revealed that the F241A mutation significantly increased galactosylation and sialylation content and glycan branching. Furthermore, overexpression of recombinant human α-2,6-sialyltransferase resulted in a predominance of α-2,6-sialylation rather than α-2,3-sialylation for both wild-type and heavily sialylated F241A antibody N-glycans. Interestingly, knocking out α-1,6-fucosyltransferase (FUT8KO), which removed core fucose, lowered the content of N-glycans with terminal Gal and increased levels of terminal GlcNAc and Man5 groups on WT antibody. Further complement-dependent cytotoxicity (CDC) analysis revealed that, regardless of the production cells, WT antibody samples have higher cytotoxic CDC activity with more exposed Gal residues compared to their individual F241A mutants. However, the FUT8KO WT antibody, with a large fraction of bi-GlcNAc structures (G0), displayed the lowest CDC activity of all WT antibody samples. Furthermore, for the F241A mutants, a higher CDC activity was observed for α-2,6- compared to α-2,3-sialylation. Antibody-dependent cellular cytotoxicity (ADCC) analysis revealed that the defucosylated WT and F241A mutants showed enhanced in vitro ADCC performance compared to their fucosylated counterparts, with the defucosylated WT antibodies displaying the highest overall ADCC activity, regardless of sialic acid substitution. Moreover, the FcγRIIIA receptor binding by antibodies did not always correspond directly with ADCC result. This study demonstrates that glycoengineering and protein engineering can both promote and inhibit antibody effector functions and represent practical approaches for varying glycan composition and functionalities during antibody development.This article is protected by copyright. All rights reserved.

biotechnology & applied microbiology

Liquid melatonin via gastrostomy as an alternative hypnotic in a child with pervasive developmental disorder.

Enhanced N-Glycan Profiling of Therapeutic Monoclonal Antibodies through the Application of Upper-Hinge Middle-Up Level LC-HRMS Analysis

Amish albinism: a distinctive autosomal recessive phenotype.

Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development

Noninvasive High-Throughput Single-Cell Analysis of the Intracellular pH of Saccharomyces cerevisiae by Ratiometric Flow Cytometry

Histochemistry of nerve fibres double labelled with anti-TRPV2 antibodies and sensory nerve marker AM1-43 in the dental pulp of rat molars.

The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies

Development and validation of a platform reduced intact mass method for process monitoring of monoclonal antibody glycosylation during routine manufacturing

Plan and process for hematology laboratory standard in Thailand.

Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform

Spectrographic representation of globular protein breathing motions.

Sculpting therapeutic monoclonal antibody N-glycans using endoglycosidases

Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering

Identifying a robust design space for glycosylation during monoclonal antibody production

Host cell proteins in monoclonal antibody processing: Control, detection, and removal

Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.

Production , Manufacturing and Logistics Multi-source facility location – allocation and inventory problem

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies

Assessment of monoclonal antibody glycosylation: a comparative study using HRMS, NMR, and HILIC-FLD

A low‐temperature SPR‐based assay for monoclonal antibody galactosylation and fucosylation assessment using FcγRIIA/B

The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions